Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.

International journal of colorectal disease - 1 Jan 2002

Park David J, Stoehlmacher Jan, Zhang Wu, Tsao-Wei Denice, Groshen Susan, Lenz Heinz-Josef

Abstract excerpt

Thymidylate synthase is a target enzyme for chemotherapeutic agents such as 5-fluorouracil and capecitabine, its oral prodrug. The human thymidylate synthase gene promoter is polymorphic, having either double or triple repeats of a 28-bp sequence. It has previously been shown that colorectal cancer patients who are homozygous for the triple tandem repeats (L/L) have significantly higher thymidylate synthase mRNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Deoxycytidine

Share to Fluorouracil

Share to Genotype

Share to Polymorphism, Genetic

Share to Thymidylate Synthase

Source

Identifiers

PMID: 12018454
DOI: 10.1007/s003840100358

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.PMID 12018454Read ↗

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy.Semantic proximity Read ↗

Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.Semantic proximity Read ↗

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.Semantic proximity Read ↗

Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.Semantic proximity Read ↗

Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.Semantic proximity Read ↗

<i>Thymidylate synthase</i>gene variations: predictive and prognostic markersSemantic proximity Read ↗

Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.Semantic proximity Read ↗

Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.Semantic proximity Read ↗

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.Semantic proximity Read ↗

Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.Semantic proximity Read ↗

Role of Single-Nucleotide Polymorphisms in Genes Implicated in Capecitabine Pharmacodynamics on the Effectiveness of Adjuvant Therapy in Colorectal Cancer.Semantic proximity Read ↗

Implication of TYMP genetic variation on the prognosis of patients with colorectal cancer who received capecitabine-based adjuvant chemotherapy after surgical resection: a real-world exploratory studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.